Technology evaluation: TransMID, KS Biomedix/Nycom...[Curr Opin Mol Ther. 2005]

SearchDatabase nameforSearch term

Advanced Search

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 1

Click to change filter selection through MyNCBI.

1: Curr Opin Mol Ther. 2005 Oct;7(5):483-92.Links

Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine.

Rainov NG, Söling A.

The University of Liverpool, Division of Neuroscience, The Walton Centre for Neurology and Neurosurgery NHS Trust, Liverpool, UK. N.G.Rainov@liverpool.ac.uk

KS Biomedix (formerly Avicenna Medica; now a subsidiary of the Xenova group) and Nycomed, together with Japanese licensee Sosei and Chinese licensee PharmaEngine, are developing TransMID, a transferrin-mediated diphtheria toxin delivery system for the potential treatment of adult, recurrent, inoperable, high-grade glioma (as TransMID-107R). It is also under investigation for other forms of brain cancer, including early brain cancer (as TransMID-107N), metastatic brain cancer (as TransMID-107M) and pediatric brain cancer (as TransMID-107P). TransMID is currently undergoing phase III clinical trials.

PMID: 16248284 [PubMed - indexed for MEDLINE]

KS Biomedix licenses TransMID brain cancer product to Nycomed in European collaboration.
Expert Rev Anticancer Ther. 2002 Oct; 2(5):481.

[Expert Rev Anticancer Ther. 2002]
ReviewClinical studies with targeted toxins in malignant glioma.
Rev Recent Clin Trials. 2006 May; 1(2):119-31.

[Rev Recent Clin Trials. 2006]
ReviewImmunotoxin treatment of brain tumors.
Methods Mol Biol. 2001; 166:139-54.

[Methods Mol Biol. 2001]
Clinical trials referral resource. Multicenter phase I and II trials in adults with high-grade gliomas.
Oncology (Williston Park). 1999 Apr; 13(4):532-3, 537.

[Oncology (Williston Park). 1999]
ReviewThe role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
Acta Neurol Belg. 2005 Sep; 105(3):137-43.

[Acta Neurol Belg. 2005]
» See reviews... | » See all...

Cited by 2 PubMed Central articles

Differential screening of phage-ab libraries by oligonucleotide microarray technology.
Monaci P, Luzzago A, Santini C, De Pra A, Arcuri M, Magistri F, Bellini A, Ansuini H, Ambrosio M, Ammendola V, et al. PLoS One. 2008 Jan 30; 3(1):e1508. Epub 2008 Jan 30.

[PLoS One. 2008]
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.
Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME. Proc Natl Acad Sci U S A. 2007 Apr 3; 104(14):5715-21. Epub 2007 Mar 22.

[Proc Natl Acad Sci U S A. 2007]

Recent Activity

Clear Turn Off Turn On

Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine.Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine.

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Display Show

Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine.

Related articles

Cited by 2 PubMed Central articles

Recent Activity